Notice NOT-CA-24-092 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-DA-25-024 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support high priority research at the intersection of HIV and substance use. This FOA invites innovative research projects with the potential to open new areas of HIV/AIDS research and/or lead to new avenues for prevention, treatment and cure of HIV among people who use drugs (PWUD). Applications submitted under this FOA are required to have a detailed research plan, preliminary data, and a clear description of the nexus with substance use. This FOA is open to both individual researchers and research teams and includes all areas of research from basic science to clinical and implementation research. All studies must focus on NIH HIV/AIDS Research Priorities: NOT-OD-20-018: UPDATE: NIH HIV/AIDS Research Priorities and Guidelines for Determining HIV/AIDS Funding.

£38,165 - £49,785 per annum: Barts Cancer Institute , Queen Mary University London: Applications are sought for a talented Bioinformatician to join the Barts Cancer Institute Bioinformatics Core Facility to provide and maintain the... London, Greater London, England

Funding Opportunity RFA-AG-25-029 from the NIH Guide for Grants and Contracts. The purpose of this NOFO is to create short courses on utilizing theNIH Stage Model to develop behavioral interventions to promote healthy aging and prevent illness, improve care, foster disease management, assist with end of life decision-making and care, and support the needs of the growing older adult population. The term behavioral intervention is used broadly here, to include a variety of non-pharmacological interventions for individuals, dyads, families, groups, communities, organizations, and systems.The NIH Stage Model is a conceptual framework of behavioral intervention development composed of six stages: basic science (Stage 0), intervention generation, refinement, modification, and adaptation and pilot testing (Stage I); traditional efficacy testing (Stage II); efficacy testing with real-world providers (Stage III); effectiveness research (Stage IV) and; dissemination and implementation research (Stage V). The goal of theNIH Stage Model is to produce potent, scalable, and culturally competent behavioral interventions that are defined by their mechanism(s) of behavior change (MoBC(s), so examination of MoBC is encouraged in every stage of intervention development. The Modelcan be used for the development of single or multi-component interventions, and for interventions meant for individuals, dyads, groups, communities, organizations, or systems. This RFA supports the development, delivery, and evaluation of a short-course curriculum to equip investigators to apply theNIH Stage Model to intervention development research.

Notice NOT-GM-24-050 from the NIH Guide for Grants and Contracts

Notice NOT-NS-24-104 from the NIH Guide for Grants and Contracts

Notice NOT-OD-24-162 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-AG-25-023 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to catalyze innovative research to elucidate the molecular landscape and functional implications of RNA modifications in brain aging and Alzheimer's disease (AD) and AD-related dementias (ADRD). AD-related dementias include Lewy body dementia (LBD), frontotemporal dementia (FTD), vascular cognitive impairment/dementia (VCI/D), and mixed dementias.This NOFO supports exploratory and developmental grant (R21) applications focused on uncovering novel mechanisms underlying RNA modification-mediated processes and their impact on brain aging and the pathogenesis of AD/ADRD. Proposed studies should focus on functional characterization and mechanistic investigation of previously identified RNA modifications.

Funding Opportunity RFA-DK-25-020 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) is a single source application for one Coordination and Data Management Center (CDMC) to continue the consortium to study Chronic Pancreatitis, Diabetes and Pancreatic Cancer (CPDPC) to conduct and complete ongoing studies on chronic pancreatitis (CP) and factors that increase the risk of pancreatic cancer in patients (children and adults) with CP, pancreatogenic (type 3c) diabetes (T3cDM) and in patients with newly diagnosed diabetes. The CPDPC is composed of several Clinical Centers (CC) and one Coordination and Data Management Center (CDMC) The Consortium since its establishment in Fall 2015 has conducted longitudinal clinical studies with comprehensive epidemiological and biological characterization of patients with CP (including those with Acute Recurrent Pancreatitis, ARP) to gain insight into the pathophysiology of chronic pancreatitis and its sequela: chronic pain, pancreatic insufficiency, T3cDM and the diabetes/pancreatic cancer association. The consortium has also undertaken studies on the development of pancreatic cancer in newly diagnosed diabetic patients. Applications for the Consortium Clinical Centers are being solicited via RFA-DK-25-019 "Continuation of the Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer Coordination and Data Coordinating Center (CPDPC-CCs) (U01) Clinical trial optional)". The CDMC along with CCs will be expected to share results freely within Consortium and to continue the trans-Consortium collaborative projects that make use of the combined expertise and technological capabilities present in all of the Consortium members (see https://cpdpc.mdanderson.org/clinicalstudies.html).

Funding Opportunity RFA-DK-25-019 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) invites U01 applications for the continuation of the consortium to study Chronic Pancreatitis, Diabetes and Pancreatic Cancer (CPDPC) to conduct and complete ongoing studies on chronic pancreatitis (CP) and factors that increase the risk of pancreatic cancer in patients (children and adults) with CP, pancreatogenic (type 3c) diabetes (T3cDM) and in patients with newly diagnosed diabetes. The CPDPC is composed of several Clinical Centers (CC) and one Coordination and Data Management Center (CDMC). The Consortium since its establishment in Fall 2015 has conducted longitudinal clinical studies with comprehensive epidemiological and biological characterization of patients with CP (including those with Acute Recurrent Pancreatitis, ARP) to gain insight into the pathophysiology of chronic pancreatitis and its sequela: chronic pain, pancreatic insufficiency, T3cDM and the diabetes/pancreatic cancer association. The consortium has also undertaken studies on the development of pancreatic cancer in newly diagnosed diabetic patients. Applications for the Consortium Coordination and Data Management Center (CDMC) are being solicited via RFA-DK-25-018 "Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer Coordination and Data Coordinating Center (CPDPC-CDMC) (U01 Clinical Trial Optional)". To effectively contribute to the ongoing CPDPC clinical studies, each CC applicant should include researchers and clinicians with multi-disciplinary expertise to match the objectives of the CPDPC (see https://cpdpc.mdanderson.org/clinicalstudies.html). Research CCs will be expected to share results freely within Consortium and to develop trans-Consortium collaborative projects that make use of the combined expertise and technological capabilities present in all of the CCs.

Funding Opportunity RFA-AG-25-022 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to catalyze innovative research to elucidate the molecular landscape and functional implications of RNA modifications in brain aging and Alzheimer's disease (AD) and AD-related dementias (ADRD). AD-related dementias include Lewy body dementia (LBD), frontotemporal dementia (FTD), vascular cognitive impairment/dementia (VCI/D), and mixed dementias. This NOFO supports applications focused on uncovering novel mechanisms underlying RNA modification-mediated processes and their impact on brain aging and the pathogenesis and progression of AD/ADRD. The ultimate goal is to identify targets for biomarker discovery and drug development for AD/ADRD.

Funding Opportunity RFA-AG-25-021 from the NIH Guide for Grants and Contracts. The goal of the Grants for Early Medical/Surgical Specialists' Transition to Aging Research (GEMSSTAR) program is to provide support for early-career physician-scientists trained in medical or surgical specialties and early-career dentist-scientists to launch careers as future leaders in aging- or geriatric-focused research. In support of the program's goal, this GEMSSTAR NOFO provides small grants to conduct transdisciplinary aging research that will yield pilot data and experience for subsequent aging research projects.

Notice NOT-OD-24-159 from the NIH Guide for Grants and Contracts

Notice NOT-GM-24-049 from the NIH Guide for Grants and Contracts

Notice NOT-OD-24-163 from the NIH Guide for Grants and Contracts

Notice NOT-CA-24-078 from the NIH Guide for Grants and Contracts

Notice NOT-HD-24-027 from the NIH Guide for Grants and Contracts

CEDARS-SINAI: Working independently but in close cooperation and in consultation with the Principal Investigator and other Research Scientists, the Postdoctoral... Los Angeles, California

CEDARS-SINAI: Working independently but in close cooperation and in consultation with the Principal Investigator and other Research Scientists, the Postdoctoral... Los Angeles, California

CEDARS-SINAI: When the work you do every single day has a crucial impact on the lives of others, every effort, every detail, and every second matters. This shar... Los Angeles, California